期刊文献+

PTEN和Her-2表达与乳腺癌长期预后的关系 被引量:1

Prognostic prediction of PTEN and Her-2 expression in breast cancer
暂未订购
导出
摘要 目的:探讨PTEN及Her-2在人原发性乳腺癌组织中表达的临床意义及其对术后生存时间的影响。方法:应用免疫组化法检测81例有15年可靠随访资料的乳腺癌石蜡标本中Her-2和PTEN的表达。采用卡方检验,Kap lan M e ier法及Log-rank检验,Cox模型回归分析等方法分析PTEN及Her-2在原发性乳腺癌组织中单独表达及共表达的临床意义。结果:(1)PTEN表达显著影响乳腺癌患者术后5年和10年的生存率(P<0.01和P<0.05);PTEN表达与Her-2显著负相关(P<0.01);(2)PTEN阴性合并Her-2阳性表达患者的5年和10年生存率显著低于PTEN阳性合并Her-2阴性表达的患者;(3)肿瘤大小、术后辅助治疗和PTEN的表达可以作为影响5年生存率有意义的风险因素(P<0.05),而ER、Her-2和PTEN的表达可以作为影响10年生存率有意义的风险因素(P<0.05)。结论:PTEN与Her-2表达可以影响乳腺癌术后生存率,Her-2和PTEN的表达可以作为分子标记物判断乳腺癌的预后。 AIM: To study the prognositic value of PTEN and Her -2 expression in primary breast cancer. METHODS: 81 breast cancer specimens with 15 years follow- up were obtained from 1989 to 2004. Immunohistochemical methods were used to detect the expression of PTEN and Her-2 in 81 paraffin- embedded specimens. The correlation between expression of PTEN and clinipathological factors was discussed with the Chi - square test. The survival rate analysis resuits were calculated with Kaplan - meier method. Long - rank test and Cox model by SPSS 10. 0 software. RESULTS : ( 1 ) PTEN expression significantly affects 5 - year and 10 - year survival rate of breast cancer ( P 〈 0. 01 and P 〈 0. 05 ) , and significantly negative correlation with the Her -2 expression was observed. (2) The patients with negative PTEN combined with positive Her- 2 expression had worse prognosis. (3) Tumor sizes, postoperative therapy and PTEN expression had significant relation with the 5 - year survival rate ( P 〈 0.05 ) , and ER, Her2 and PTEN expression had significant relation with the 10 - year survival rate ( P 〈 0. 05 ). CONCLUSION : PTEN and Her - 2 expression significantly affects 5 - year and 10 - year survival rate in patients with breast cancer, and may be biomarkers and important prognostic factors in breast cancer.
出处 《中国病理生理杂志》 CAS CSCD 北大核心 2006年第12期2380-2384,共5页 Chinese Journal of Pathophysiology
关键词 乳腺肿瘤 预后 PTEN基因 HER-2基因 Breast neoplasms Prognosis Genes, PTEN Genes, Her-2
  • 相关文献

参考文献12

  • 1李雪玲,王一飞.NM23基因与乳腺癌转移关系的研究进展[J].中国病理生理杂志,2003,19(3):418-422. 被引量:4
  • 2Goussia AC, Stefanou D, Agnantis NJ. The role of tumor markers in non - palpable breast cancers [ J ]. Eur J Gynaecol Oncol, 2004, 25 (5) : 559 - 561.
  • 3Gradishar WJ. The future of breast cancer: the role of prognostic factors[ J ]. Breast Cancer Res Treat, 2005, 89(1): 17-26.
  • 4Crowder R J, Lombardi DP, Ellis MJ. Successful targeting of ErbB2 receptors - is PTEN the key? [ J ]. Cancer Cell,2004, 6 ( 2 ) : 103 - 10d.
  • 5吴元清,魏启幼.PTEN在乳腺癌研究中的进展[J].国外医学(生理病理科学与临床分册),2003,23(6):577-580. 被引量:9
  • 6王晓玫,成志强,王玲,苏学劲,陈灼怀.CD44s在肺癌中的表达及其意义[J].中国病理生理杂志,2004,20(8):1489-1491. 被引量:3
  • 7Sledge GW Jr. HERe-2 stay: The continuing importance of translational research in breast cancer[ J ]. J Natl Cancer Inst, 2004, 96(10) : 725 -727.
  • 8Marsh DJ, Coulon V, Lunetta KL, et al. Mutation spectrum and genotype phenotype analyses in Cowden disease and Bannayan Zonana syndrome,two hamartoma syndromes with gertime PTEN mutation[J]. Hum Mol Genet, 1998,7(3) : 507 -515.
  • 9Ggarcia JM, Silva JM, Dominguez G, et al. Allelic loss of the PTEN region ( 10q23 ) in breast carcinoma of poor pathophentype[J]. Breast Cancer Res Treat, 1999, 57(3) : 237 - 243.
  • 10Bose S, Wang SI, Terry MB, et al. Allelic loss of chromsome 10q23 is assnciatied with tumor progression in breast carcinomas[J]. Oncogene, 1998, 17(1): 123-127.

二级参考文献41

  • 1Gao AC, Lon W, Dong JT, et al. CD44 is a metastasis suppressor gene for prostatic cancer located on human chromosome11 p13[J]. Cancer Res, 1997, 57(4):846- 849.
  • 2Fasano M, Sabatini MT, Wieczorek R, et al. CD44 and its v6spliced variant in lung tumors: a role in histogenesis[ J]. Cancer, 1997, 80(1):34-41.
  • 3Kondo K, Miyoshi T, Hino N, et al. High frequency expression of CD44 standard and variant forms in non - small cell lung cancers, but not in small cell lung cancer[ J]. J Surg Oncol, 1998, 69(3): 128 - 136.
  • 4Ochiai S, Nakanishi Y, Mizuno K, et al. Expression of CD44standard and CD44 variant 6 in human lung cancer[ J]. Nihon Kyobu Shikkan Gakkai Zasshi, 1997, 35(11): 1179- 1185.
  • 5Naor D, Sionov RV, lsh- Shalon D, et al. CD44: structure,function and association with the malignant process[ J ]. Adv Cancer Res, 1997,71(10) :241 - 242.
  • 6Granberg D, Wilander E, Oberg K, et al. Decreased survival in patients with CD44- negative typical bronchial carcioid tumons[J]. Int J Cancer, 1999, 84(5) :484 - 488.
  • 7Lee J, Georgescu M, Di Cristofano A, et al. Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association [ J ]. Cell, 1999,99 ( 3 ):323 -334.
  • 8Maehama T, Dixon JE. The tumor suppressor,PTEN/MMAC1 ,dephosphorilates the lipid second messenger, phosphatidylinosital-3,4,5-trisphosphate [ J ]. J Biol Chem, 1998, 273 ( 22 ): 13375-13378.
  • 9Wu X, Hepner K, Castelino-Prabhu S, et al. Evidence for regulation of the PTEN tumor suppressor by a membrane-localized multiPDZ domain containing scaffold protein MAGI-2 [ J]. Proc Natl Acad Sic USA,2000, 97 ( 8 ) :4233-4238.
  • 10Georgescu M, Kirsch K, Adage T, et al. The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region[ J]. Cell Biology, 1999, 96( 18 ): 10182-10187.

共引文献13

同被引文献5

引证文献1

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部